Blue Cross Blue Shield · Injectafer · US health-plan appeal rights

Injectafer denied as not FDA-approved for this use by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Injectafer denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

Blue Cross Blue Shield's specific coverage criteria for injectafer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: BCBS Iron Therapy in HFrEF — IV Ferric Carboxymaltose

The Blue Cross Blue Shield angle on Injectafer

## Why a "Not FDA-Approved" Denial for Injectafer Is Almost Always an Error

Injectafer (ferric carboxymaltose) holds FDA approval for specific indications in adult patients. A denial stating that Injectafer is "not FDA-approved" from BlueCross BlueShield almost invariably reflects one of three administrative errors: (1) the plan's system incorrectly coded the drug or indication, (2) the denial was triggered by an off-label use flag without a proper clinical review, or (3) an outdated coverage policy is in use. In any of these scenarios, the denial is a strong appeal candidate.

## Why This Denial Is Appealable

If Injectafer is being prescribed for an FDA-approved indication, the plan's denial on "not FDA-approved" grounds is factually incorrect and must be reversed. Even in cases where an off-label use is involved, the not-FDA-approved denial category is frequently inappropriate: off-label use of an FDA-approved drug is legal, common in clinical practice, and covered under many plans when supported by published clinical evidence and applicable professional society guidelines. The applicable standard under ACA §2719 and ERISA §503 is whether the treatment is consistent with generally accepted standards of medical practice — not whether it carries a specific labeled indication.

## Federal Appeal Framework

Internal appeal: File immediately under ERISA §503 or ACA §2719. Request the specific basis for the not-FDA-approved determination, including any clinical policy document or reviewer notes.
External review: If denied internally, escalate to an IRO. IROs are required to apply generally accepted standards of medical practice; for an FDA-approved drug used in an evidence-supported manner, this denial category rarely survives external review.
Expedited review: Request expedited processing if the patient's anemia is symptomatic or clinically urgent.

## Concrete Appeal Steps and Timeline

1. Confirm from the current Injectafer prescribing label (available via the FDA) the exact approved indications. 2. Confirm whether the prescribed use falls within an approved indication or is off-label. 3. If on-label: the denial is a clear factual error; submit the FDA label with the internal appeal. 4. If off-label: assemble evidence of guideline support and clinical necessity (see documentation below). 5. File the internal appeal by the deadline on the denial letter; escalate to IRO if denied.

## Documentation to Gather

FDA prescribing label: A copy of or reference to the current Injectafer label confirming the approval status for the relevant indication.
Diagnosis confirmation: Lab results and clinical notes establishing the qualifying diagnosis and its severity.
Guideline support (if off-label use): Reference to the applicable professional society (e.g., relevant hematology, nephrology, or gastroenterology organization) guideline supporting this use.
Prescriber letter: Explicit statement from the treating physician confirming the indication, the FDA-approval status, and the clinical basis for prescribing — including reference to supporting clinical evidence if off-label.

## Criteria-Mapping Structure

Request from BCBS the specific definition of "not FDA-approved" as used in the denial. Build a two-column response: left column reproduces each element of that definition; right column provides the FDA label reference, chart documentation, or guideline citation that refutes the denial criterion directly. Not-FDA-approved denials for approved drugs are among the most straightforward to overturn when properly documented.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other insurers on Injectafer

Other denial reasons for Blue Cross Blue Shield Injectafer

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.